DRUG vs MPLT
DRUG: Bright Minds Biosciences is a clinical-stage biotechnology company developing next-generation serotonin-targeting therapies for neuropsychiatric, epilepsy, and pain conditions. MPLT: MapLight Therapeutics is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel, targeted treatments for central nervous system disorders.
Side-by-side fundamentals
| Metric | DRUG | MPLT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $75.46 | $35.31 | |
| Market cap as of 2026-07-23 | $762M | $1.6B | |
| PEG as of 2026-07-23 | -0.06 | n/a | |
| ROE as of 2026-07-23 | -20.6% | -35.2% | DRUG higher |
| ROA as of 2026-07-23 | -20.3% | -33.6% | DRUG higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | MPLT lower |
| Beta as of 2026-07-23 | 2.30 | 1.45 | |
| 1-year return as of 2026-07-22 close | -74.8% | +113.2% | MPLT higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.